# Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis

> **NCT02424734** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 11 (actual)

## Conditions studied

- Late-onset Sepsis

## Interventions

- **DRUG:** Ceftaroline Fosamil
- **DRUG:** Ampicillin
- **DRUG:** Aminoglycoside

## Key facts

- **NCT ID:** NCT02424734
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-04
- **Primary completion:** 2017-12-26
- **Final completion:** 2017-12-26
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Study was terminated on 22Dec2017 due to slow enrollment; there were no safety or efficacy concerns.
- **Last updated:** 2018-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02424734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02424734, "Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02424734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*